265 related articles for article (PubMed ID: 28625555)
1. Adjuvant pertuzumab improves early breast cancer outcomes.
Das M
Lancet Oncol; 2017 Jul; 18(7):e378. PubMed ID: 28625555
[No Abstract] [Full Text] [Related]
2. Trastuzumab emtansine for HER2-positive breast cancer.
Venkatesan P
Lancet Oncol; 2016 Dec; 17(12):e528. PubMed ID: 27866859
[No Abstract] [Full Text] [Related]
3. Neoadjuvant Therapy for HER2-positive Breast Cancer.
Wuerstlein R; Harbeck N
Rev Recent Clin Trials; 2017; 12(2):81-92. PubMed ID: 28164759
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Gianni L; Pienkowski T; Im YH; Roman L; Tseng LM; Liu MC; Lluch A; Staroslawska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi G; Szado T; Ratnayake J; Ross G; Valagussa P
Lancet Oncol; 2012 Jan; 13(1):25-32. PubMed ID: 22153890
[TBL] [Abstract][Full Text] [Related]
5. Why the results of adjuvant pertuzumab in HER2-positive early breast cancer has been received as a mitigate success?
Pivot X; Cox DG; Gligorov J
Chin Clin Oncol; 2018 Feb; 7(1):1. PubMed ID: 29156890
[No Abstract] [Full Text] [Related]
6. Pertuzumab in HER2-positive early breast cancer: current use and perspectives.
Eiger D; Pondé NF; de Azambuja E
Future Oncol; 2019 Jun; 15(16):1823-1843. PubMed ID: 30938542
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant trastuzumab for breast cancer. Better to stick with proven treatments.
Prescrire Int; 2013 Feb; 22(135):39. PubMed ID: 23444499
[TBL] [Abstract][Full Text] [Related]
8. Pertuzumab for the treatment of breast cancer.
Robert M; Frenel JS; Bourbouloux E; Berton Rigaud D; Patsouris A; Augereau P; Gourmelon C; Campone M
Expert Rev Anticancer Ther; 2020 Feb; 20(2):85-95. PubMed ID: 30884986
[No Abstract] [Full Text] [Related]
9. T-DM1 in the Neo-Adjuvant Treatment of HER2-Positive Breast Cancer: Impact of the KRISTINE (TRIO-021) Trial.
Okines AF
Rev Recent Clin Trials; 2017; 12(3):216-222. PubMed ID: 28552047
[TBL] [Abstract][Full Text] [Related]
10. [Pertuzumab (Perjeta®) approval in HER2-positive metastatic breast cancers].
Sabatier R; Gonçalves A
Bull Cancer; 2014; 101(7-8):765-71. PubMed ID: 25091659
[TBL] [Abstract][Full Text] [Related]
11. Systemic therapy for HER2-positive early-stage breast cancer.
Mathew A; Romond EH
Curr Probl Cancer; 2016; 40(2-4):106-116. PubMed ID: 27816189
[TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Inhibition in Metastatic Urothelial Cancer.
Powles T; Smith K; Stenzl A; Bedke J
Eur Urol; 2017 Oct; 72(4):477-481. PubMed ID: 28413128
[TBL] [Abstract][Full Text] [Related]
13. Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?
Constantinidou A; Smith I
Breast; 2011 Oct; 20 Suppl 3():S158-61. PubMed ID: 22015286
[TBL] [Abstract][Full Text] [Related]
14. Optimizing Anti-HER2 Therapy in early breast cancer: updates from the KRISTINE trial.
Hennessy MA; Morris PG
Ann Palliat Med; 2020 Mar; 9(2):504-509. PubMed ID: 32233616
[No Abstract] [Full Text] [Related]
15. Patients with anti-HER2 responsive disease: definition and adjuvant therapies.
Burstein HJ
Breast; 2011 Oct; 20 Suppl 3():S132-4. PubMed ID: 22015280
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant capecitabine for HER2-negative breast cancer.
Burki TK
Lancet Oncol; 2017 Jul; 18(7):e375. PubMed ID: 28602775
[No Abstract] [Full Text] [Related]
17. Advances in targeting HER2-positive breast cancer.
Harbeck N
Curr Opin Obstet Gynecol; 2018 Feb; 30(1):55-59. PubMed ID: 29194077
[TBL] [Abstract][Full Text] [Related]
18. Adverse Mucocutaneous Reaction to Pertuzumab in a Patient with HER2-Positive Metastatic Breast Cancer.
Kowalczyk L; Singer CF; Staudigl C; Weber M; Farr A
Breast J; 2017 May; 23(3):352-353. PubMed ID: 27563723
[No Abstract] [Full Text] [Related]
19. Beyond trastuzumab: new treatment options for HER2-positive breast cancer.
Saini KS; Azim HA; Metzger-Filho O; Loi S; Sotiriou C; de Azambuja E; Piccart M
Breast; 2011 Oct; 20 Suppl 3():S20-7. PubMed ID: 22015288
[TBL] [Abstract][Full Text] [Related]
20. Pertuzumab and its accelerated approval: evolving treatment paradigms and new challenges in the management of HER2-positive breast cancer.
O'Sullivan CC; Connolly RM
Oncology (Williston Park); 2014 Mar; 28(3):186-94, 196. PubMed ID: 24855725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
